ClinicalTrials.gg
WithdrawnNCT03137030Updated Jul 21, 2017

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults

A Phase 1 interventional study of GRT7014 - Abuse Deterrend Tablet and Norco 5Mg-325Mg Tablet in Opioid-Related Disorders, Pain, Acute and Pain, Postoperative, sponsored by Grünenthal GmbH. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-21.

Sponsored by Grünenthal GmbH · Phase 1, Interventional, and Treatment

Why this study was withdrawn
program discontinued

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,222 studies in Opioid-Related Disorders with a site in United States — 245 open to participants now, 315 under way, 18 of them phase 3. Opioid-Related Disorders · United States.

Enrollment
1,004th of 1,097
0 · median 56
Started
2017
with 42 others
Phase 1
132 of 1,222
24 open now
Registered
416th of 1,222
by date

Among the 1,222 studies in Opioid-Related Disorders with a site in United States, this one is the 1,004th largest by enrollment of the 1,097 interventional ones that give a count, is one of 43 that started in 2017, is one of 132 in phase 1, and was the 416th registered.

Opioid-Related Disorders

1,473 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

245 of the 1,222 studies in Opioid-Related Disorders with a site in United States are open now. Recruiting first, the newest first:

240 more — sign in →

All 245 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 210 Opioid-Related Disorders studies recruiting now, 122 (58%) set no upper age limit and 74 (35%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,222 studies in Opioid-Related Disorders with a site in United States, or all of them as a file.
02

Study summary

This clinical trial is being conducted to compare concentrations of hydrocodone and acetaminophen in the blood after administration of different amounts of tablets of a new and a marketed tablet formulation in healthy adults.

Part 1 is a randomized, single-site, open-label, 4-treatment, 4-period crossover, single oral dose Phase I trial in 32 healthy male and female subjects. Part will consist of an Enrollment Visit, 4 treatment periods (each lasting approximately 90 hours), and a Final Examination. The treatment periods will be separated by a washout period each lasting at least 7 days.

Part 2 is optional and depending on pharmacokinetic data review after Part 1. It is a randomized, single-site, open-label, 2-treatment, 2-period crossover, single oral dose part in healthy male and female subjects. Part 2 will consist of an Enrollment Visit, 2 treatment periods (each lasting approximately 90 hours) and a Final Examination. The treatment periods will be separated by a washout period lasting at least 7 days.

Participants must fast for approximately 10 hours prior to administration of Investigational medicinal product (IMP) and until approximately 4 hours after the administration of the IMP.

03

Conditions studied

  • Opioid-Related Disorders
  • Pain, Acute
  • Pain, Postoperative

Keywords

  • Abuse deterrent formulation
  • Hydrocodone
  • Analgesics, Opioid
  • Narcotics
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects have given written to participate.
  • between 20 kg/m2 and 30 kg/m2 inclusive, with a minimal body weight of 60 kg.
  • Subjects must be in good health as determined by the medical history, physical and laboratory examinations and must not show any deviations from reference ranges as determined by 12-lead (ECG), vital signs (blood pressure, pulse rate, respiratory rate), body temperature, oxygen saturation, and safety laboratory parameters (hematology, clinical chemistry, clotting, and urinalysis).
  • From the first administration of IMP until at least 4 weeks (for women)/90 days (for men) after the Final Examination, subjects must agree to use highly effective with a low failure rate defined as \<1% per year.
  • For female subjects of :

    • Combined (estrogen and progestogen containing) hormonal contraception.
    • Progestogen-only hormonal contraception associated with inhibition of ovulation.
    • An intra-uterine device (hormone-free).
    • An intra-uterine hormone releasing system (IUS).
    • Bilateral tubal occlusion.

Women of non-childbearing potential may be included if surgically sterile (i.e., after hysterectomy or bilateral oophorectomy) or for at least 12 months (i.e., spontaneous amenorrhea at least 1 year prior to screening with confirmed follicle-stimulating hormone level >40 IU/L).

For male subjects:

Male subjects have to use barrier contraception (condom) during sexual intercourse with women of childbearing potential from the first application of IMP until at least 90 days after the Final Examination. The male subject has to be willing to ensure that the female sexual partner uses at least 1 additional method of contraception with a low failure rate defined as \<1% per year until at least 90 days after the Final Examination.

Exclusion criteria

Exclusion Criteria:

  • Withdrawal of .
  • Received forbidden medication or an medical device since the Enrollment Visit.
  • Any relevant deterioration in the health of the subject since the Enrollment Visit possibly impacting participation in the trial at the discretion of the investigator, including: adverse events; vital signs (relevant out-of-reference blood pressure or pulse rate if technical failure can be excluded and result is confirmed by at least 1 additional measurement); physical examination, 12-lead (relevant prolongation if result is confirmed by 1 additional ECG measurement and manual re-evaluation by the investigator); other safety parameters.
  • Blood loss of 100 mL or more since enrollment in this trial (excluding blood taken for this trial).
  • Resting pulse rate \<50 beats per minute or >90 beats per minute.
  • Resting systolic blood pressure \<90 mmHg or >140 mmHg. Resting diastolic blood pressure >90 mmHg.
  • Prolongation of corrected QT interval (according to Fridericia's formula; QTcF), i.e., QTcF >450 ms or presence of other of risk factors for torsade de pointes.
  • Evidence for thyroid disease based on clinical and safety laboratory findings, including thyroid-stimulating hormone.
  • Any laboratory value (from blood samples taken at the Enrollment Visit) meeting the following criteria:

    • Out-of-reference range value for , aspartate transaminase, alkaline phosphatase, total , glucose (fasted), gamma-glutamyl transferase, serum creatinine, , and international normalized ratio.
    • Exclusion range met for urinalysis or lactate dehydrogenase, potassium, total protein, sodium, calcium, , hematocrit, white blood cell count, or .
    • Out-of-reference range value for any other safety laboratory parameter that is judged as by the investigator.
    • A single repeat laboratory test (for each out-of-range parameter) is allowed to rule out laboratory error.
  • Positive or missing virus serology test (in blood sample taken at the Enrollment Visit) for Type 1 or Type 2 antibodies, surface antigen, (HBsAg), hepatitis B core antigen antibodies (anti-HBc), or virus antibodies.
  • For women of only: positive or missing pregnancy test.
  • Subject received IMP in another clinical trial (when assessing for Part 2, excludes IMP received in Part 1 of this trial) within 30 days before the Enrollment Visit. Depending on the nature of the previous IMP, a longer washout may be needed.
  • Diseases or conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
  • History of orthostatic hypotension.
  • History of, or at risk of seizures (i.e., head trauma, epilepsy in family history, unclear loss of consciousness).
  • Definite or suspected to the active substance or to any of the of the IMP; especially known hypersensitivity/intolerance or to opioids, opioid antagonists, acetaminophen or any excipients of the drug formulation.
  • Evidence or history of alcohol or drug abuse including positive or missing alcohol breath test or drugs of abuse test.
  • Unable to abstain from regular use of any medication, including herbal remedies or over-the-counter medication within 2 weeks prior to the Enrollment Visit and anticipated use during the course of the trial, excluding oral in women of childbearing potential and topical medications or nasal sprays without systemic effect.
  • Lactating or breastfeeding women.
  • Habitually smoking more than 10 cigarettes, 2 cigars, or 2 pipes of tobacco per day within the last 6 months before enrollment in this trial.
  • Unable to refrain from smoking during the stay at the trial site in each treatment period.
  • Not willing or able to abstain from consumption of:

    • Beverages or food containing methylxanthines (tea, coffee, cola, chocolate, etc.) from 48 hours prior to the planned first administration of IMP until discharge from the trial site in each treatment period.
    • Beverages or food containing quinine (bitter lemon, tonic water), grapefruit juice (sweet or sour), Seville oranges, or alcohol from 72 hours prior to the planned first administration of IMP until discharge from the trial site in each treatment period.
  • Known or suspected of not being able to comply with the requirements of the trial protocol or the instructions of the trial site staff.
  • Not able to communicate meaningfully with the trial site staff.
  • Employee of the investigator or trial site, with direct involvement in the proposed trial or other trials under the direction of that investigator or trial site, as well as family members of the employees or the investigator.
  • Blood loss of 500 mL or more within 45 days before enrollment in this trial.
  • Unable to establish reliable venous access.
  • Medical history of bronchial asthma, Addison's disease, prostatic hypertrophy, or urethral stricture.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    GRT7014 - 1 Tablet (Part 1)

    Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet. (GRT7014 - Abuse Deterrend Tablet)

    Drug: GRT7014 - Abuse Deterrend Tablet

  • Experimental
    GRT7014 - 10 Tablets (Part 1)

    Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet. (GRT7014 - Abuse Deterrend Tablet)

    Drug: GRT7014 - Abuse Deterrend Tablet

  • Active comparator
    Norco - 1 Tablet (Part 1)

    Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).

    Drug: Norco 5Mg-325Mg Tablet

  • Active comparator
    Norco - 10 Tablets (Part 1)

    Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).

    Drug: Norco 5Mg-325Mg Tablet

  • Experimental
    GRT7014 - 5 Tablets (Optional Part 2)

    Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet. (GRT7014 - Abuse Deterrend Tablet)

    Drug: GRT7014 - Abuse Deterrend Tablet

  • Active comparator
    Norco - 5 Tablets (Optional Part 2)

    Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).

    Drug: Norco 5Mg-325Mg Tablet

Interventions

  • DrugGRT7014 - Abuse Deterrend Tablet

    Drug pages: Hydrocodone · Acetaminophen

    Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.

    Also known as: Hydrocodone bitartrate and acetaminophen

  • DrugNorco 5Mg-325Mg Tablet

    Drug pages: Hydrocodone · Acetaminophen

    Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.

    Also known as: Hydrocodone bitartrate and acetaminophen

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) GRT7014 (1 and 10 Tablets)

    The maximum plasma concentration of hydrocodone and of acetaminophen.

    Time frame: Between 0 hours and 72 hours

  2. Area under the plasma concentration curve from timepoint 0 to t (AUC0-t) GRT7014 (1 and 10 Tablets)

    The area under the plasma concentration curve of hydrocodone and of acetaminophen.

    Time frame: Between 0 hours and 72 hours

  3. Area under the plasma concentration curve from timepoint 0 to infinity (AUC) GRT7014 (1 and 10 Tablets)

    The area under the plasma concentration curve of hydrocodone and of acetaminophen.

    Time frame: Between 0 hours and 72 hours

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) GRT7014 and Norco (1, 5 (optional) and 10 Tablets)

    The maximum plasma concentration of hydrocodone and of acetaminophen.

    Time frame: Between 0 hours and 72 hours

  2. Area under the plasma concentration curve from timepoint 0 to t (AUC0-t) GRT7014 and Norco (1, 5 (optional) and 10 Tablets)

    The area under the plasma concentration curve of hydrocodone and of acetaminophen.

    Time frame: Between 0 hours and 72 hours

  3. Area under the plasma concentration curve from timepoint 0 to infinity (AUC) GRT7014 and Norco (1, 5 (optional) and 10 Tablets)

    The area under the plasma concentration curve of hydrocodone and of acetaminophen.

    Time frame: Between 0 hours and 72 hours

07

Study locations

1 site
  • US001: PRA Health Sciences
    Lenexa, Kansas 66219, United States
08

References and documents

Individual participant data

Plan to share: No — Details available at: http://www.grunenthal.com/grt-web/Grunenthal_Group/Research_Development/Grunenthal_Clinical_Trials/Data_Sharing/296200025.jsp

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2017; primary completion for Jan 2018, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2017
First posted
May 2, 2017
StartEst.
Sep 2017
Primary completionEst.
Jan 2018
CompletionEst.
Jan 2018
Last update
Jul 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03137030
Lead sponsor
Grünenthal GmbH
Responsible party
Sponsor
First posted
May 2, 2017
Start date
Sep 2017 (estimated)
Primary completion
Jan 2018 (estimated)
Completion
Jan 2018 (estimated)
Last update
Jul 21, 2017

Study contacts

Grünenthal Study Director
study director · Grünenthal GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Hydrocodone · Acetaminophen

Start the discussion